Epidemiological distribution of high-risk human papillomavirus genotypes and associated factors among patients with esophageal carcinoma at Bugando medical center in Mwanza, Tanzania, BMC Cancer ...

Esophageal cancer causes more than half a million cancer-related deaths worldwide each year, 1 with squamous-cell carcinoma accounting for approximately 85% of cases. 2 Many esophageal cancers are ...

Barrett's esophagus is a premalignant lesion detected in the majority of patients with esophageal and gastroesophageal adenocarcinoma — cancers that are associated with a low rate of survival (5 ...

New England Journal of Medicine. Volume 347 • Number 21 • November 21, 2002. ... Multimodality Treatment for Potentially Resectable Esophageal Cancer, Shackelford's Surgery of the Alimentary ...

Quick Take Video Summary from The New England Journal of Medicine — Nivolumab in Esophageal or Gastroesophageal Junction Cancer. ... Esophageal cancer causes more than half a million deaths each ...

NEJM This Week — January 23, 2025. Featuring articles on esophageal cancer, out-of-hospital cardiac arrest, and atrial fibrillation; a review article on the physiology of hunger; ...

The current concerns about esophageal cancer were triggered in January 2009 when the Food and Drug Administration reported in the New England Journal of Medicine that it had received 23 reports of ...

The study will be published Thursday in The New England Journal of Medicine.. The results mark “the first true advance” in the post-surgical treatment of esophageal cancer and “will become a ...

The risk of developing esophageal cancer for those with Barrett’s Esophagus is lower than previously thought, according to a new study published in the New England Journal of Medicine. Using the ...

Comparative risks for cancer associated with use of calcitonin, bisphosphonates or selective estrogen receptor modulators among osteoporosis patients: a population-based cohort study, Japanese ...

Previously untreated patients with advanced esophageal cancer were randomly assigned to receive chemotherapy alone, chemotherapy plus nivolumab, or nivolumab plus ipilimumab. Among patients with ...